Naproxe (Naprosyn, Aleve, Anaprox)
Supportive Care · Approved since 1976
Description
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that belongs to the propionic acid class and is being evaluated for cancer prevention in patients with Lynch syndrome who are at high risk for developing colorectal cancer. The medication works as a cyclooxygenase inhibitor and has shown potential in preventing DNA mismatch repair deficient colorectal cancers. Naproxen is primarily used for pain and inflammation management but has demonstrated chemopreventive properties in hereditary cancer syndromes.
Mechanism of Action
Naproxen inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, reducing prostaglandin synthesis and inflammatory responses. In the context of colorectal cancer prevention, naproxen's anti-inflammatory effects may help suppress tumor-promoting inflammation and reduce cancer development in high-risk individuals with Lynch syndrome.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Naprosyn, Aleve, Anaprox |
| Category | Supportive Care |
 Status | Off-label |
| Administration | Oral |
| Year Approved | 1976 |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.